Cytotoxic activity of G3 PAMAM-NH 2 dendrimer-chlorambucil conjugate in human breast cancer cells

Environmental Toxicology and Pharmacology

Volumn 32, Issue 3, 2011, Pages 364-372

  Bielawski, Krzysztof ^a   Bielawska, Anna ^a   Muszyńska, Anna ^a   Popławska, Bozena ^a   Czarnomysy, Robert ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Breast cancer; Chlorambucil; Collagen biosynthesis; PAMAM dendrimer

Indexed keywords

CHLORAMBUCIL; CYTOTOXIC AGENT; LIPOCORTIN 5; POLYAMIDOAMINE CHLORAMBUCIL CONJUGATE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CELL STRAIN MCF 7; COLLAGEN SYNTHESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION;

ANNEXIN A5; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHLORAMBUCIL; COLLAGEN; DENDRIMERS; FEMALE; HUMANS;

EID: 80054091268     PISSN: 13826689     EISSN: 18727077     Source Type: Journal    
DOI: 10.1016/j.etap.2011.08.002     Document Type: Article

References (31)

1. Agarwal A., Asthana A., Gupta U., Jain N.K. Tumour and dendrimers: a review on drug delivery aspects. J. Pharm. Pharmacol. 2008, 60:671-688.
2. Leukaran® (Chlorambucil). Current Clinical Guide 1993, 37-45. Borroughts Wellcome Co./Oncology Products Wellcome Oncology NCM Publ., NY. second ed. J.O. Armitage (Ed.).
3. Baker J.R. Dendrimer-based nanoparticles for cancer therapy. Hematology 2009, 1:708-719.
4. Carmichael J., Degraff W., Gazdar A., Minna J., Mitchell J. Evaluation of a tetrazolinium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 1987, 47:936-942.
5. Cohen J.J., Duke R.C., Fadok V.A., Sellins K.S. Apoptosis and programmed cell death in immunity. Annu. Rev. Immunol. 1992, 10:267-293.
6. Coward P., Wada H.G., Falk M.S., Chan S.D.H., Meng F., Akil H., Conklin B.R. Controlling signaling with a specifically designed Gi-coupled receptor. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:352-357.
7. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 2006, 6:688-701.
8. Duncan R., Izzo L. Dendrimer biocompatibility and toxicity. Adv. Drug Deliv. Rev. 2005, 57:2215-2237.
9. Farmer P.B. Metabolism and reactions of alkylating agents. Pharmacol. Ther. 1987, 301-358.
10. Gonzalez M.G., Bhattacharya R., Hard W.G., Jones J.C.R. Transdominant regulation of integrin function: mechanisms of crosstalk. Cell. Signal. 2010, 22:578-583.
11. Gurdag S., Khandare J., Stapels S., Matherly L.H., Kannan R.M. Activity of dendrimer-methotrexate conjugates on methotrexate-sensitive and resistant cell lines. Bioconj. Chem. 2006, 17:275-283.
12. Hall A.G., Tilby M.J. Mechanisms of action, and modes of resistance to alkylating agents used in the treatment of haematological malignancies. Blood Rev. 1992, 6:163-173.
13. Khandare J.J., Jayant S., Singh A., Chandna P., Wang Y., Vorsa N., Minko T. Dendrimer versus linear conjugate: influence of polymeric architecture on the delivery and anticancer effect of paclitaxel. Bioconj. Chem. 2006, 17:1464-1472.
14. Khandare J.J., Kolhe P., Pillai O., Kannan S., Lieh-Lai M., Kannan R.M. Synthesis, cellular transport, and activity of polyamidoamine dendrimer-methylprednisolone conjugates. Bioconj. Chem. 2005, 16:330-337.
15. Kociecka B., Surazynski A., Miltyk W., Palka J. The effect of telmisartan on collagen biosynthesis depends on the status of estrogen activation in breast cancer cells. Eur. J. Pharmacol. 2010, 628:51-56.
16. Kurtoglu Y.E., Mishra M.K., Kannan S., Kannan R.M. Drug release characteristics of PAMAM dendrimer-drug conjugates with different linkers. Int. J. Pharm. 2010, 384:189-194.
17. Malik N., Evagorou E.G., Duncan R. Dendrimer-platinate: a novel approach to cancer chemotherapy. Anticancer Drugs 1999, 10:767-776.
18. Mamoto A., Ingber D.E. Cytoskeletal control of growth and cell fate switching. Curr. Opin. Cell Biol. 2009, 21:864-870.
19. Najlah M., Freeman S., Attwood D., D'Emanuele A. Synthesis, characterization and stability of dendrimer prodrugs. Int. J. Pharm. 2006, 308:175-182.
20. Navath R.S., Kurtoglu Y.E., Wang B., Kannan S., Romero R., Kannan R.M. Dendrimers-drug conjugates for tailored intracellular drug release based on glutathione levels. Bioconj. Chem. 2008, 19:2446-2455.
21. Oyamada I., Pałka J., Schalk E.M., Takeda K., Peterkofsky B. Scorbutic and fasted guinea pig sera contain an insulin-like growth factor I reversible inhibitor of proteoglycan and collagen synthesis in chick embryo chondrocytes and adult human skin fibroblasts. Arch. Biochem. Biophys. 1990, 276:85-93.
22. Patri A.K., Kukowska-Latallo J.F., Baker J.R. Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex. Adv. Drug Deliv. Rev. 2005, 57:2203-2214.
23. Pedersen P.J., Christensen M.S., Ruysschaert T., Linderoth L., Andresen T.L., Melander F., Mouritsen O.G., Madsen R., Clausen M.H. Synthesis and biophysical characterization of chlorambucil anticancer ether lipid prodrugs. J. Med. Chem. 2009, 52:3408-3415.
24. Peterkofsky B., Pałka J., Wilson S., Takeda K., Shah V. Elevated activity of low molecular weight insulin-like growth factor-binding proteins in sera of vitamin C-deficient and fasted guinea pigs. Endocrinology 1991, 128:1769-1779.
25. Roberts J.C., Bhalgat M.K., Zera R.T. Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst dendrimers. J. Biomed. Mater. Res. 1996, 30:53-65.
26. Svenson S. Dendrimers as versatile platform in drug delivery applications. Eur. J. Pharm. Biopharm. 2009, 71:445-462.
27. Tomalia D.A., Reyna L.A., Svenson S. Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging. Biochem. Soc. Trans. 2007, 35:61-67.
28. Vermes I., Haanen C., Steffens-Nakken H., Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J. Immunol. Methods 1995, 184:39-51.
29. Westermann B. Molecular machinery of mitochondrial fusion and fission. J. Biol. Chem. 2008, 283:13501-13505.
30. Winnicka K., Bielawski K., Bielawska A. Synthesis and cytotoxic activity of G3 PAMAM-NH2 dendrimer-modified digoxin and proscillaridin A conjugates in breast cancer cells. Pharm. Rep. 2010, 62:414-423.
31. Winnicka K., Bielawski K., Rusak M., Bielawska A. The effect of generation 2 and 3 poly(amidoamine) dendrimers on viability of human breast cancer cells. J. Health Sci. 2009, 55:169-177.